Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From what I've read, this mutated stain is actual more infectious, you don't get any sicker, but are more likely to get it. This may be the perfect storm for us. When Remdesivir was approved the cases were around 24k/day, now were over 50k/day and climbing. The US bought the whole supply of Remdesivir, now they need more medicine, medicine that works. LERONLIMAB... We have over 10 years of safety, and based on all the EIND use, it works. The Gov can't ignore it forever, I feel now is our time. The US is out of options.
I don't have Twitter, but if someone could ask him what the status of BP's peer review submission is, that would be fantastic.
New Trademark:
But look who it used to belong to.
On Monday, May 14, 2007, a U.S. federal trademark registration was filed for IMMUVANCE. The USPTO has given the IMMUVANCE trademark serial number of 77179766. The current federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED. The correspondent listed for IMMUVANCE is Nadine P. Flynn of BRISTOL-MYERS SQUIBB COMPANY, TRADEMARK DEPARTMENT, 345 PARK AVENUE NEW YORK NY 10154 . The IMMUVANCE trademark is filed in the category of Pharmaceutical Products . The description provided to the USPTO for IMMUVANCE is Fiber supplement for infant formula.
Mark Image
Word Mark IMMUVANCE
Goods and Services IC 005. US 006 018 044 046 051 052. G & S: therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor
IC 042. US 100 101. G & S: scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor
IC 044. US 100 101. G & S: providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
Mark Drawing Code (0) UNKNOWN
Serial Number 88956377
Filing Date June 9, 2020
Current Basis 1B
Original Filing Basis 1B
Owner (APPLICANT) CytoDyn Inc. CORPORATION DELAWARE Suite 660 1111 Main Street Vancouver WASHINGTON 98660
Attorney of Record Jared M. Barrett
Description of Mark The mark consists of a representation of an abstracted antibody on a circular background shown adjacent to the term IMMUVANCE in stylized letters.
Type of Mark TRADEMARK. SERVICE MARK
Register PRINCIPAL
Live/Dead Indicator LIVE
What does that mean near term?
...and said?
$7.16 pre-market 10.49% up!
Thank you for the response
Thank you for your insight
Do you think we would be uplisted by FDA approval? Would that not prevent them from driving it down like they did
So, what is your short term forecast, now that this massive short attack occurred? Will they allow to regain growth before attempting again, or will they continue to strike now that we have been weakened?
Tom since we didn't retrace yesterday's lows. How are the charts looking, Macd, bb, RSI?
That was for the emergency ind group. Not this trial
I don't recall him saying both trials.
You called a lot of things lately! I hope the correction is done, and we can start back on our journey. From reading some posts, some mentioned the company threatened legal action, I hope is true and will deter the shorts from continuing.
Thanks Tom,
Always happy to read your posts.
RSI is now 57.94 from 95.45
Heading back up
Hopefully we can have a run like nvax did. Within 6 months went from $3.98-$83.61
Giliad to charge $3120 for a product that doesn't work!
https://www-wsj-com.cdn.ampproject.org/v/s/www.wsj.com/amp/articles/covid-19-drug-remdesivir-to-cost-3-120-for-typical-patient-on-private-insurance-11593428402?amp_js_v=a3&_gsa=1&usqp=mq331AQFKAGwASA%3D#referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fcovid-19-drug-remdesivir-to-cost-3-120-for-typical-patient-on-private-insurance-11593428402
Ugh what?
CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
I think so, look at the high volume of buying. 140m shares issued and it's trading 80k, and that's high volume day!
Did someone offer the company a fast $100? US of course.
7m volume in an hour, and back over $7!
Just under 5m in volume in 30 min.
Thanks Tom, always appreciated
Hey Tom,
What are you seeing with the chart these days?
$4.77
Who says I'm not a shareholder already?
You said there was a dollar figure mentioned that was turned down, why wouldn't shareholders get to vote on that figure
Wow the CEO just offered that information? Why wasn't the offer presented to shareholders?
Could be possible with a buy out/ partnership. NPs recent action with extending severance could be telling
$4.25
$4.19
$4.03!
Yes,
New company will want to insert it's own management. They would most likely offer Dr. P. a position to stay on.
That was my thinking as well.
New 8k out, looks like a modification to Naders' severance package, from 12-18 months.
Expecting to get booted?
https://www.cytodyn.com/investors/sec-filings
Lol, not me guy.
$.041??? 48% down, sub pennies coming soon!
To add to that point, and insult to injury. The management used it as an ATM, and after there was nothing sued the company which serval individuals involved in this company are listed, including the CEO.